Properties (59)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Acquired_by_Madrigal_Pharmaceuticals
|
| gptkbp:advertising |
Develops market strategies for product launch
|
| gptkbp:businessModel |
Aims for business growth through innovation.
Focused on drug development and commercialization |
| gptkbp:CEO |
gptkb:Safi_Bahcall
|
| gptkbp:clinicalTrials |
Conducted multiple clinical trials for drug development
Collects clinical data for drug efficacy Drugs in various clinical phases Focus on developing new cancer therapies Innovative drug discovery approaches Ongoing clinical trials for drug candidates Completed_several_clinical_trials |
| gptkbp:collaborations |
Collaboration with various research institutions
Collaborations with academic institutions Engaged in collaborative research projects |
| gptkbp:drugInterdiction |
Developing multiple drug candidates
Focus on drug safety and efficacy Navigates_the_drug_approval_process_with_regulatory_bodies |
| gptkbp:enrollment |
Targets specific patient populations for therapies
|
| gptkbp:feedback |
Aims to improve clinical outcomes for patients
|
| gptkbp:financialPerformance |
Reports financial performance quarterly
|
| gptkbp:financials |
Publicly traded with financial disclosures
Operates in the biotechnology sector |
| gptkbp:focus |
cancer therapeutics
|
| gptkbp:founded |
2007
|
| gptkbp:founder |
gptkb:Safi_Bahcall
|
| gptkbp:headquarters |
gptkb:Lexington,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Synta Pharmaceuticals
|
| gptkbp:industry |
Biotechnology
|
| gptkbp:investmentFocus |
Various institutional investors
Maintains investor relations for stakeholders Invested in research and development Invests in research for new therapies |
| gptkbp:keyPeople |
gptkb:Safi_Bahcall
gptkb:Richard_A._Heyman gptkb:David_M._Hyman |
| gptkbp:location |
gptkb:United_States
|
| gptkbp:market |
Global pharmaceutical market
Market capitalization fluctuates with stock performance |
| gptkbp:notableEvent |
gptkb:elesclomol
|
| gptkbp:partnerships |
Formed strategic partnerships with other companies
Partnership with other biotech firms |
| gptkbp:patentCitation |
Holds multiple patents for drug formulations
|
| gptkbp:productLine |
Developing drugs for various cancers
|
| gptkbp:products |
Pipeline includes several investigational drugs
|
| gptkbp:publications |
Published research in scientific journals
|
| gptkbp:regulatoryCompliance |
Seeking regulatory approvals for drugs
|
| gptkbp:research |
Conducts scientific research in oncology
|
| gptkbp:research_areas |
Oncology
oncology Innovations in cancer treatment Explores various therapeutic approaches in oncology |
| gptkbp:research_focus |
Mitochondrial function in cancer
|
| gptkbp:sells |
gptkb:NASDAQ
|
| gptkbp:stockExchange |
SNTA
|
| gptkbp:subsidiary |
gptkb:Synta_Pharmaceuticals,_Inc.
|
| gptkbp:type |
public company
|
| gptkbp:website |
www.syntapharma.com
|